Higher dose of Novartis' Stalveo cleared in USA

12 August 2007

Swiss drug major Novartis says that the US Food and Drug Administration has approved a new, higher-dose strength of Stalevo (carbidopa, levodopa and entacapone) which is indicated for Parkinson's disease patients with signs and symptoms of end-of-dose wearing off.

The approval of Stalevo 200mg, which consists of 50mg carbidopa, 200mg levodopa, 200mg entacapone, provides physicians with greater dosing flexibility in the treatment of PD patients experiencing symptom re-emergence, Novartis noted, adding that the introduction of this new dosage strength may lessen the burden of managing multiple medications among patients and their caregivers.

Stalevo simplifies treatment because it combines levodopa, the most widely-used agent for treating PD, with carbidopa and entacapone to provide more consistent and reliable levels of levodopa to the brain. The addition of entacapone to levodopa delays the breakdown of levodopa and extends the duration of effect of each dose. The firm noted that Stalevo significantly improves PD patients' ability to control body movements and to perform basic functions, such as walking and dressing, compared to traditional levodopa therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight